The German biotechnology company and Covid-19 vaccine manufacturer, BioNTech, will be starting the construction of its Southeast Asian headquarters in Singapore this year and expecting site operation to start by 2023.
BioNTech announced on Monday that they are scheduled to start constructing its facility in Singapore once approval was given by the authorities.
“Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities,” Ugur Sahin, CEO and co-founder of BioNTech, said on Monday.
“With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world,” Sahin added.
BioNTech’s planned Southeast Asia headquarters will also be manufacturing novel mRNA vaccines as well as treatment for other infectious diseases and cancer.
The manufacturing facility is expected to open up at least 80 jobs in the domestic market but can increase more depending on the size and speed of setting up the facility.
Singapore’s Economic Development Board (EDB) supports BioNTech’s expansion project. The company had earlier expanded its facility by setting up its U.S. headquarters in Cambridge, Massachusetts in 2020.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.